Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-10-30

Clinical Trial Update: Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men [Phase 3]

View source ↗

Summary

Open-label Phase 3 follow-up study of oral testosterone undecanoate in men with hypogonadism.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Oral testosterone undecanoate (testosterone undecanoate)

Snippet

Sponsor: Clarus Therapeutics, Inc. | Conditions: Male Hypogonadism | Phase 3 | Status: COMPLETED | Results posted: 2018-10-30